Mkts

Beam Therapeutics Inc.

NASDAQ: BEAM
$27.12+0.71 (+2.69%)
As of Nov 9, 2:34 PM ET

Key statistics

Day range
25.9527.37
52-week range
20.2338.26
Today
Open26.61
Previous close27.12
Volume—
Valuation
Market cap2.73B
P/E ratio—
EPS (TTM)-0.81
Income & risk
Dividend / yield—
Beta2.24
Avg volume1.96M
Discussion

BEAM News

Stories mentioning BEAM from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue31,738114,1099,6988,4667,47030,06714,26911,772
Cost of Goods Sold
Gross Profit
Operating Expenses
Research & Development104,52499,275109,769101,75898,816101,44494,25887,041
Sales General & Admin
Total Operating Expenses138,953131,554136,509128,617126,756130,104120,773116,667
Operating Income (Loss)(107,215)(17,445)(126,811)(120,151)(119,286)(100,037)(106,504)(104,895)
Interest Income
Interest Expense
Other Expense
Pretax Income(112,728)(102,291)(96,668)(91,012)
Tax Provision0.000.0039.00
Net Income (Loss)(94,318)243,357(112,728)(102,291)(108,330)(90,354)(96,668)(91,051)
Earnings Per Share (Basic)(0.91)2.46(1.10)(1.00)(1.23)(1.10)(1.17)(1.11)
Earnings Per Share (Diluted)(0.91)2.46(1.10)(1.00)(1.23)(1.10)(1.17)(1.11)
Weighted Average Shares Outstanding (Basic)103,26298,906102,571101,99587,97582,31382,41082,312
Weighted Average Shares Outstanding (Diluted)103,26298,906102,571101,99587,97582,31382,41082,312

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About BEAM

Beam Therapeutics Inc. (NASDAQ: BEAM) is a stock listed on the Nasdaq Stock Market under the ticker symbol BEAM. It last traded at $27.12 (Nov 9, 2026, 2:34 PM ET), up 2.7% on the day. That gives Beam Therapeutics a market capitalisation of $2.7B.

Over the past 52 weeks BEAM has traded between $20.23 and $38.26.

Revenue for the quarter ended Mar 31, 2026 was $31.7M; a net loss of $94.3M. Revenue was up 325% from $7.5M in the quarter ended Mar 31, 2025.

Last 4 quarters
Quarter endedRevenueNet incomeMargin
Mar 31, 2026$31.7M-$94.3M-297.2%
Dec 31, 2025$114.1M$243.4M213.3%
Sep 30, 2025$9.7M-$112.7M-1162.4%
Jun 30, 2025$8.5M-$102.3M-1208.3%

From Beam Therapeutics’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…